Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sullivan

Showing results (1181-1190 of 1,317) with videos related to

Pageof 132
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 15, 2006
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonistsM Cui, P Honore, C Zhong, et al.
Inorganic Chemistry|February 20, 2020
Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl<sub>2</sub> ComplexesDianna Truong, Matthew P Sullivan, Kelvin K H Tong, et al.
Cell Reports|June 4, 2020
Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and CytotoxicityJulia A Wagner, Pamela Wong, Timothy Schappe, et al.
Contemporary Clinical Trials|March 20, 2019
Design and recruitment of the randomized order safety trial evaluating resident-physician schedules (ROSTERS) studyTerri Blackwell, Dana R Kriesel, Eric Vittinghoff, et al.
Geroscience|May 10, 2022
Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patientsAyush Batra, Jeffrey R Clark, Anthony K Kang, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective propertiesJ P Sullivan, D Donnelly-Roberts, C A Briggs, et al.
British Journal of Pharmacology|August 11, 2004
In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892Murali Gopalakrishnan, Steven A Buckner, Char-Chang Shieh, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing propertiesN H Lin, D E Gunn, K B Ryther, et al.
The American Journal of Sports Medicine|August 2, 2020
Incidence and Predictors of Subsequent Surgery After Anterior Cruciate Ligament Reconstruction: A 6-Year Follow-up Study, Jaron P Sullivan, Laura J Huston, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterizationMurali Gopalakrishnan, Steven A Buckner, Kristi L Whiteaker, et al.
Pageof 132

Showing results (1181-1190 of 1,317) with videos related to

Sort By:
Pageof 132
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 15, 2006
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonistsM Cui, P Honore, C Zhong, et al.
Inorganic Chemistry|February 20, 2020
Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl<sub>2</sub> ComplexesDianna Truong, Matthew P Sullivan, Kelvin K H Tong, et al.
Cell Reports|June 4, 2020
Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and CytotoxicityJulia A Wagner, Pamela Wong, Timothy Schappe, et al.
Contemporary Clinical Trials|March 20, 2019
Design and recruitment of the randomized order safety trial evaluating resident-physician schedules (ROSTERS) studyTerri Blackwell, Dana R Kriesel, Eric Vittinghoff, et al.
Geroscience|May 10, 2022
Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patientsAyush Batra, Jeffrey R Clark, Anthony K Kang, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective propertiesJ P Sullivan, D Donnelly-Roberts, C A Briggs, et al.
British Journal of Pharmacology|August 11, 2004
In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892Murali Gopalakrishnan, Steven A Buckner, Char-Chang Shieh, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing propertiesN H Lin, D E Gunn, K B Ryther, et al.
The American Journal of Sports Medicine|August 2, 2020
Incidence and Predictors of Subsequent Surgery After Anterior Cruciate Ligament Reconstruction: A 6-Year Follow-up Study, Jaron P Sullivan, Laura J Huston, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterizationMurali Gopalakrishnan, Steven A Buckner, Kristi L Whiteaker, et al.
Pageof 132